Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13263991 | 0.84 | HTR2A (0.35) | HTR2AHTR2CHTR2BCYP3A4KIF11 | |
| SCHEMBL31155329 | 0.83 | MEN1 (0.35) | CYP3A4KIF11AR | |
| SCHEMBL12109792 | 0.83 | CYP3A4 (0.34) | CYP3A4 | |
| SCHEMBL13263826 | 0.77 | CYP3A4 (0.35) | CYP3A4 | |
| SCHEMBL13557209 | 0.76 | HTR2A (0.40) | HTR2AHTR2CHTR2BCYP3A4KIF11 | |
| SCHEMBL9342725 | 0.76 | KIF11 (0.41) | KIF11 | |
| SCHEMBL424780 | 0.74 | KIF11 (0.40) | KIF11 | |
| SCHEMBL7271102 | 0.73 | KIF11 (0.39) | HTR2AHTR2CKIF11 | |
| SCHEMBL20690107 | 0.72 | CYP3A4 (0.32) | CYP3A4 | |
| SCHEMBL10310070 | 0.70 | CYP2D6 (0.36) | CYP3A4KIF11ARDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | HTR2A 514/4885HTR2C 808/4885HTR2B 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.